Immunovant, inc.IMVT.US Overview

US StockHealthcare

(No presentation for IMVT)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

IMVT Overall Performance

IMVT AI Analysis & Strategy

IMVT Recent Performance

-0.86%

Immunovant, inc.

0.81%

Avg of Sector

-1.14%

S&P500

IMVT PowerScanner

IMVT Key Information

IMVT Valuation Metrics

IMVT Earnings Table

IMVT Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.